Paricalcitol in Fabry Disease

N/ACompletedNCT02090608

Federico II University14 enrolled

Overview

Proteinuria is the predominant risk factor for renal disease progression in Fabry disease (FD). When urine protein excretion is controlled to \<0.50 g/24 hr, the rate loss of glomerular filtration rate (GFR) is not significantly different from 0. However, enzyme replacement therapy (ERT) alone does not decrease proteinuria and it has been recommended that patients receiving ERT also receive anti Renin-Angiotensin-System (RAS) therapy. Emerging evidences show that paricalcitol (PCT) reduces proteinuria in presence of intensified inhibition of RAS; however, there is no evidence in FD. The aim of this study is to evaluate the antiproteinuric effect of PCT in FD patients with proteinuria \>0.50 g/24 hr persisting despite the ERT and anti-RAS therapy titrated to maximum tolerated dosage.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Fabry Disease Proteinuria

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * genetically proven FD * stable dose of ERT for at least 12 months * stable dose of ACEi or ARB titrated to maximum tolerated dosage for at least 6 months * persistent proteinuria \>0.50 g/24 h despite the use of ERT and ACEi/ARBs in 2 consecutive samples within 12 weeks Exclusion Criteria: * steroid/immunosuppressive treatment or glomerular filtration rate change \>30% in the past 3 months * PTH levels \<20 pg/mL * serum phosphorus \>5.0 mg/dL * serum calcium (adjusted for albumin) \>10.0 mg/dL * active malignancy.

Outcomes

Primary Outcomes

Effect of paricalcitol on proteinuria reduction

Fourteen Fabry patients will be selected and studied in the first six months of add-on oral PCT (1 mcg/day) and, in order to verify the dependence of proteinuria reduction on PCT, three months after drug withdrawal.

Time frame: 6 months